ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

FATE Fate Therapeutics Inc

1.6802
0.0202 (1.22%)
21 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Fate Therapeutics Inc NASDAQ:FATE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0202 1.22% 1.6802 1.62 3.00 1.80 1.6404 1.675 10,135,980 05:00:11

Fate Therapeutics to Present at Upcoming December Investor Conferences

26/11/2024 9:01pm

GlobeNewswire Inc.


Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart


From Dec 2024 to Dec 2024

Click Here for more Fate Therapeutics Charts.

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences:

  • Citi’s 2024 Global Healthcare Conference, including a panel discussion at 2:30 PM ET on Tuesday, December 3, 2024 in Miami, Florida; and
  • Piper Sandler’s 36th Annual Healthcare Conference, including a panel discussion at 3:00 PM ET and a fireside chat at 4:00 PM ET on Wednesday, December 4, 2024 in New York, New York.

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:Christina TartagliaPrecision AQ212.362.1200christina.tartaglia@precisionaq.com

1 Year Fate Therapeutics Chart

1 Year Fate Therapeutics Chart

1 Month Fate Therapeutics Chart

1 Month Fate Therapeutics Chart

Your Recent History

Delayed Upgrade Clock